Arginine Vasopressin Contents of the Hypothalamus and Pituitary during Fetal and Postnatal Development in the Mouse. (mouse/radioimmunoassay/vasopressin/neurosecretion)

The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions

The hypothalamic-pituitary-adrenal axis is a complex system of neuroendocrine pathways and feedback loops that function to maintain physiological homeostasis. Abnormal development of the hypothalamic-pituitary-adrenal (HPA) axis can further result in long-term alterations in neuropeptide and neurotransmitter synthesis in the central nervous system, as well as glucocorticoid hormone synthesis in the periphery. Together, these changes can potentially lead to a disruption in neuroendocrine, behavioral, autonomic, and metabolic functions in adulthood. In this review, we will discuss the regulation of the HPA axis and its development. We will also examine the maternal-fetal hypothalamic-pituitary-adrenal axis and disruption of the normal fetal environment which becomes a major risk factor for many neurodevelopmental pathologies in adulthood, such as major depressive disorder, anxiety, schizophrenia, and others.

Effects of alcohol and psychostimulants on the vasopressin system: behavioral implications

Drug addiction is a chronic brain disease characterized by a compulsion to seek drugs, a loss of control with respect to drug consumption, and negative emotional states, including increased anxiety and irritability during withdrawal. Central vasopressin (AVP) and its receptors are involved in controlling social behavior, anxiety and reward, all of which are altered by drugs of abuse. Hypothalamic AVP neurons influence the stress response by modulating the hypothalamic-pituitary-adrenal (HPA) axis. The extrahypothalamic AVP system, however, is commonly associated with social recognition, motivational and anxiety responses. The specific relationship between AVP and drugs of abuse has been rarely reviewed. Here, we provide an overview of the interaction between the brain AVP system and psychostimulants and alcohol. We focus on the effects of alcohol and psychostimulants on AVP regulation of the HPA axis, their effect on the brain AVP system and their behavioral implications, the influence of the AVP system on addictive behaviors, AVP's organizational effects on the brain and consequently on behavior, and we highlight clinical studies on the relation between the AVP system and drug addiction. Finally, we discuss the data to address areas that need further research to support clinical trials and prevent drug-related disorders. This article is protected by copyright. All rights reserved.

Developmental perspectives on oxytocin and vasopressin

The related neuropeptides oxytocin and vasopressin are involved in species-typical behavior, including social recognition behavior, maternal behavior, social bonding, communication, and aggression. A wealth of evidence from animal models demonstrates significant modulation of adult social behavior by both of these neuropeptides and their receptors. Over the last decade, there has been a flood of studies in humans also implicating a role for these neuropeptides in human social behavior. Despite popular assumptions that oxytocin is a molecule of social bonding in the infant brain, less mechanistic research emphasis has been placed on the potential role of these neuropeptides in the developmental emergence of the neural substrates of behavior. This review summarizes what is known and assumed about the developmental influence of these neuropeptides and outlines the important unanswered questions and testable hypotheses. There is tremendous translational need to understand the functions of these neuropeptides in mammalian experience-dependent development of the social brain. The activity of oxytocin and vasopressin during development should inform our understanding of individual, sex, and species differences in social behavior later in life.

Ontogeny of the vasopressin and oxytocin RNAs in the mouse hypothalamus

The single-copy genes encoding the vasopressin and oxytocin prepropeptides are closely linked in mouse genome, being separated by an intergenic region of only 3 kbp. These genes are expressed in anatomically defined hypothalamic neurons--in the adult rodent, vasopressin is synthesised in the paraventricular nucleus and the supraoptic nucleus, and in the dorsomedial region of the suprachiasmatic nucleus, whilst oxytocin is expressed in the supraoptic nucleus and paraventricular nucleus, but not in the suprachiasmatic nucleus. The molecular mechanisms that mediate the cell-specific and developmental expression patterns of the two transcription units within the vasopressin-oxytocin locus remain to be elucidated. As a first step in this process, we have used in situ hybridisation to study the expression of the RNAs encoded by the linked vasopressin and oxytocin genes during the development of the mouse hypothalamus. We have revealed a hierarchy of gene activation events, with vasopressin first being observed in presumptive supraoptic nucleus at day 13.5, and in the paraventricular at day 14.5. Oxytocin is seen first in the paraventricular at day 15.5; expression in the supraoptic nucleus is clearly seen at day 18.5. As early as day 15.5, the vasopressin and oxytocin RNAs are expressed in different groups of neurons.

Vasopressin and oxytocin gene expression in intact rats and under catecholamine deficiency during ontogenesis

The development of the hypothalamic vasopressin (VP) and oxytocin (OT) systems has been studied in rats from the 16th embryonic day (E16) until the 11th postnatal day (P11). The VP and OT mRNA-producing neurons were identified on cryostat sections by in situ hybridization using oligonucleotide probes labeled by [35S], [3H] or digoxigenin. Moreover, VP and OT gene expressions were evaluated either at E21 or at P11 following chronic depletion of catecholamines (CA). For this purpose, pregnant rats were daily injected with alpha-methyl-m(p)-tyrosine from gestational day 13 to 20 while neonates were daily injected with alpha-methyl-m(p)-tyrosine and neurotoxin 6-hydroxydopamine from postnatal day 2 to 10. No VP mRNA- or OT mRNA-expressing cells were observed in the hypothalamus of intact fetuses at E16, while 2 days later rather numerous VP and OT neurons occupied the anterior hypothalamus. One major bilateral group of VP and OT neurons was located in the supraoptic nucleus (SON). Less numerous labeled cells were found in the developing paraventricular nucleus (PVN). Some VP and OT neurons were also spread along the ventrolateral surface of the hypothalamus from the level of the median eminence, caudally, to the level of the optic nerves, rostrally. From E18 until birth, the OT neurons were localized in the dorsal portion of the SON, while its ventral portion was occupied by the VP neurons. The VP mRNA- and OT mRNA-expressing cells seemed to increase both in size and in number over the perinatal period. Frequent relatively long neuronal processes contained VP and OT mRNAs in fetuses and in newborns. When performed during the second half of the fetal life, the chronic depletion of CA did not cause any change in the VP and OT mRNA concentrations in the SON and PVN of fetuses. By contrast, similar treatment of neonates resulted in a significant increase of both mRNA levels in the SON. These data suggest that at least in the SON VP and OT gene expression might be under the inhibitory control of CA during the neonatal period.

Expression of provasopressin gene during ontogeny in the hypothalamus of developing mice

We investigated the ontogeny of provasopressin gene expression in neurosecretory neurons of the supraoptic and paraventricular nuclei of developing mice by semi-quantitative in situ hybridization and immunohistochemical techniques in combination with stereometry of vasopressin-immunoreactive neurons. Provasopressin mRNA was detected in paraffin sections using a mixture of radiolabeled synthetic oligonucleotide probes complementary to the mRNA loci encoding vasopressin (2-9) and vasopressin neurophysin (1-8). Vasopressin immunoreactivity was located with a polyclonal anti-vasopressin antiserum and a monoclonal anti-vasopressin-neurophysin antibody either with or without enhancing technique for the diaminobenzidine reaction. Autoradiographic hybridization signals that indicate the localization of provasopressin mRNA were first detected on embryonic day 15 in the supraoptic nucleus and embryonic day 18 in the paraventricular nucleus. Vasopressin immunoreactivity was first found in the median eminence on embryonic day 14, and then in the supraoptic and paraventricular nuclei on embryonic days 15 and 16, respectively. The provasopressin mRNA levels were markedly increased in both the supraoptic and the paraventricular nuclei just after birth. The immunoreactivity of vasopressin neurons was drastically decreased in both nuclei on postnatal days 1 and 2, suggesting marked vasopressin release in the neonates. Cross-sectional areas of vasopressin-immunoreactive somata and their cell nuclei gradually increased in both the supraoptic and the paraventricular nuclei during the perinatal period by day 5, and then attained adult size between days 10 and 20. During this phase, the level of provasopressin mRNA remained low compared with that in the adult magnocellular neurosecretory cells. These results indicate that the expression of provasopressin gene is markedly increased in both the supraoptic and the paraventricular nuclei soon after birth. Secretory activity of vasopressin neurons is elevated in neonatal mice. Vasopressin may have an important osmoregulatory role in neonatal mice undergoing drastic changes in water metabolism following birth.

Circadian changes in arginine vasopressin level in the suprachiasmatic nuclei in the rat

Arginine vasopressin (AVP) neurons were preferentially localized in the dorsomedial part of the suprachiasmatic nucleus (SCN). To know the role of AVP neurons in the SCN, male rats were kept under a normal light-dark cycle (L-D), or under constant darkness (D-D) for 20 days. In L-D condition, AVP levels in the SCN showed the circadian change. In D-D condition, the patterns in AVP levels showed a free-running rhythm, and an about 12-h shift per 20 days. This result suggests that the activity of AVP neurons may be closely associated with the endogenous circadian rhythm of the SCN.

Changes in arginine vasotocin content in the pituitary of the Medaka (Oryzias latipes) during osmotic stress

Changes in the arginine vasotocin (AVT) neurons of the medaka, Oryzias latipes, during osmotic stress were studied by means of immunohistochemistry and radioimmunoassay. AVT neurons were identified by their immunoreactivity to anti-arginine vasopressin serum, which crossreacts with AVT. When freshwater (FW)-adapted fish were transferred to seawater (SW), the number of immunoreactive magnocellular neurons decreased, while the cell nuclear size increased. AVT content in the pituitary significantly decreased 2 hr or 1 day after transfer to SW, but returned to approximately the initial level 1 week after transfer. However, when SW-adapted fish were transferred to FW, the number of immunoreactive magnocellular neurons increased from 1 hr after readaptation to FW, but the cell nuclear size failed to show significant changes. AVT content in the pituitary significantly increased 1 or 2 hr after transfer. These results seem to indicate that AVT secretion in the medaka was temporarily accelerated by exposure to SW and inhibited immediately after transfer to FW.